Corbus Pharmaceuticals Holdings Inc (CRBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.08-3.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRBP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | — | — | — | 0.0 | 0.9 | 3.9 | 36.1 | 4.8 | 2.4 | 1.9 | 0.6 | — |
| Total Revenues | — | — | — | — | — | — | — | — | 4.8 | 2.4 | 1.9 | 0.6 | — |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 90.3 | 70.1 | 32.2 | 31.2 | 16.1 | 36.4 | 98.3 | 89.6 | 48.6 | 26.0 | 15.4 | 5.9 | 1.3 |
| Operating Income | (106.9) | (85.3) | (48.7) | (45.1) | (39.8) | (56.0) | (122.8) | (77.1) | (56.7) | (32.6) | (20.0) | (8.9) | (2.6) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | 1.9 | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | 1.2 | — | — | — | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | (0.0) | 0.0 |
| Other Non-Operating Income / Expenses | 5.0 | 6.8 | 8.5 | 0.5 | (2.5) | 10.3 | 11.5 | 5.7 | 1.1 | 0.1 | (0.0) | 0.0 | 0.1 |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||||
| Minority Interest | — | (78.5) | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | (101.9) | (78.5) | (40.2) | (44.6) | (42.3) | (45.6) | (111.3) | (71.5) | (55.7) | (32.4) | (20.0) | (8.9) | (2.5) |
| Per Share | |||||||||||||
| Basic EPS | (5.25) | (5.90) | (3.68) | (10.31) | (10.15) | (11.15) | (1.42) | — | — | — | — | — | — |
| Diluted EPS | (5.25) | (5.90) | (3.68) | (10.31) | (10.15) | (11.15) | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 19.4 | 13.3 | 10.9 | 4.3 | 4.2 | 4.1 | 78.1 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 19.4 | 13.3 | 10.9 | 4.3 | 4.2 | 4.1 | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (85.1) | (48.1) | (44.4) | (39.1) | (55.0) | (121.7) | (76.4) | (56.3) | (32.3) | (19.9) | — | — |
| EBIT | (106.9) | (85.3) | (48.7) | (45.1) | (39.8) | (56.0) | (122.8) | (77.1) | (56.7) | (32.6) | (20.0) | (8.9) | (2.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.